Results for this period
Interim period (second quarter)1 October 2025–31 March 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company received a milestone achievement payment and joint research funding from Ono Pharmaceutical Co., Ltd. Selling, general and administrative expenses were ¥666.565 million, and research and development expenses were ¥456.744 million. Year-on-year changes are provided for both.
Disclosure of material events and other matters is included. Although events or circumstances exist that raise substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and negative operating cash flow, the company believes that there is no material uncertainty regarding the going concern assumption. No note on the going concern assumption is applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 October 2025–31 March 2026 |
| Net Sales | ¥253 million (YoY +15.8%) |
| Operating profit | ¥-584 million |
| Ordinary income | ¥-560 million |
| Profit attributable to owners of the parent | ¥-603 million |
| Net income per share | −16.34 yen |
| Equity ratio | End of the current fiscal period 81.8 / End of previous period 87.6 |
| Total assets | ¥2,586 million |
| Net assets | ¥2,129 million |
| Cash flows from operating activities | ¥-462,510 thousand |
| Cash flows from investing activities | ¥-1,535,462 thousand |
| Cash flows from financing activities | ¥17,303 thousand |
| Cash and cash equivalents at end of period | ¥954,487 thousand |
| Annual Dividend Forecast | 0 yen and sen → 0 yen and sen |
| Impairment loss | ¥41,804 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥99 thousand, Impairment Losses ¥41,804 thousand |
| Disclosure regarding the going concern assumption | Disclosure of material events and other matters is included. Although events or circumstances exist that raise substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and negative operating cash flow, the company believes that there is no material uncertainty regarding the going concern assumption. No note on the going concern assumption is applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts, and for general investors) |
| Issued Shares at Period-End | 36,964,000 Shares |
| Factors Behind Changes in Business Performance | The company received a milestone achievement payment and joint research funding from Ono Pharmaceutical Co., Ltd. Selling, general and administrative expenses were ¥666.565 million, and research and development expenses were ¥456.744 million. Year-on-year changes are provided for both. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company received a milestone achievement payment and joint research funding from Ono Pharmaceutical Co., Ltd. On the expense side, selling, general and administrative expenses increased, including a 55.0% year-on-year increase in research and development expenses.